Zacks Investment Research upgraded shares of Vernalis (OTCMKTS:VNLPY) from a hold rating to a buy rating in a report released on Saturday. They currently have $0.25 price target on the stock.
According to Zacks, “Vernalis Group plc is a research and development-stage pharmaceutical company based in Oxford, UK, which is developing drugs for the treatment of unmet medical needs such as cancer and inflammatory and infectious diseases. The main technology platform is inhibition of metalloenzymes which will be supplemented through the addition of externally-generated programs. “
Vernalis (VNLPY) opened at $0.26 on Friday. The company has a market cap of $62.54, a P/E ratio of -2.36 and a beta of 0.59. Vernalis has a 12 month low of $0.26 and a 12 month high of $0.61.
COPYRIGHT VIOLATION WARNING: “Vernalis (VNLPY) Upgraded to Buy by Zacks Investment Research” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.com-unik.info/2018/01/09/vernalis-vnlpy-upgraded-to-buy-by-zacks-investment-research-2.html.
Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vernalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis and related companies with MarketBeat.com's FREE daily email newsletter.